ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
Go back to ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial| (NASDAQ: PRQR) | Delayed: 1.89 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.89 | 52 Week High | $13.33 | |||
| Open | $1.89 | 52 Week Low | $3.48 | |||
| Day High | $1.98 | P/E | N/A | |||
| Day Low | $1.88 | EPS | $0.00 | |||
| Volume | 379,719 | |||||
